Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Alemtuzumab

    ... Alemtuzumab is a drug used in the treatment of chronic lymphocytic ... which these lymphocytes are derived. After treatment with alemtuzumab, these CD52-bearing lymphocytes are targeted for destruction. ...

    Drug last updated 03/26/2016 - 8:15pm.

  2. Rational Management Approach To Pure Red Cell Aplasia

    ... in hypogammaglobulinemia cases. In salvage settings, alemtuzumab is active, particularly in large granular lymphocytic leukemia ... salvage agents such as intravenous immunoglobulin, alemtuzumab and bortezomib. LINK to Journal ...

    Research Article last updated 12/14/2017 - 10:12am.

  3. Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm

    ... therapy, including the anti-CD52 antibody alemtuzumab . We analyzed treatment responses to alemtuzumab in 5 patients with MDS or aplastic anemia (AA) evolving to MDS. ...

    Research Article last updated 11/01/2016 - 1:56pm.

  4. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia

    ... the humanized anti-CD52 monoclonal antibody , alemtuzumab , might be active in SAA due to its lymphocytotoxic properties. To test this hypothesis, we investigated alemtuzumab monotherapy from 2003-2010 in treatment-naïve, relapsed, and ...

    Research Article last updated 11/16/2011 - 1:57pm.

  5. Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation.

    ... This retrospective national study compared the use of alemtuzumab -based conditioning regimens for hematopoietic SCT (HSCT) in ... (ATG)-based regimens. One hundred patients received alemtuzumab and 55 ATG-based regimens. A matched sibling donor (MSD) was used ...

    Research Article last updated 08/15/2013 - 9:45am.

  6. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft versus host disease after allogeneic stem cell transplantation for acquired aplastic anemia.

    ... We evaluated a novel alemtuzumab -based conditioning regimen in hematopoietic stem cell ... 4 days, cyclophosphamide 300mg/m(2) for 4 days and alemtuzumab median total dose of 60mg (range:40-100mg). Median age was 35 ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Allogeneic stem cell transplantation using alemtuzumab-containing regimens in severe aplastic anemia.

    ... Alemtuzumab , a humanized anti-CD52, IgG1 monoclonal antibody , is ... severe aplastic anaemia (SAA). We have reviewed the use of alemtuzumab-based conditioning regimen for HSCT in SAA and show that it results ...

    Research Article last updated 06/20/2013 - 10:30am.

  8. Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab

    Journal Title:  Semin Hematol Primary Author:  Parikh AR Author(s):  Parikh A...

    Research Article last updated 11/05/2012 - 9:48am.

  9. Paroxysmal nocturnal hemoglobinuria following alemtuzumab immunosuppressive therapy for myelodysplastic syndrome and complicated by recurrent life-threatening thrombosis despite anticoagulation: successful intervention with eculizumab and fondaparinux

    Journal Title:  Leuk Res. Primary Author:  Cheng KL Author(s):  Cheng KL, Br...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Eltrombopag for the treatment of aplastic anemia: current perspectives

    ... globulin, high-dose cyclophosphamide , and alemtuzumab . Eltrombopag, a thrombopoietin mimetic, has recently emerged as ...

    Research Article last updated 11/01/2016 - 2:01pm.